Perrigo announces settlement of generic version of Dymistaź nasal spray patent litigation
Perrigo announced it has settled the Hatch-Waxman litigation relating to Dymistaź (azelastine hydrochloride and fluticasone propionate) nasal spray brought by Meda Pharmaceuticals and Cipla. Annual market sales for the twelve months ending May 2017 were $152 million. July 17, 2017